阜阳皮肤病医院哪个好阜阳哪里看痤疮好啊,阜阳治疗痤疮医院哪家好,阜阳县县医院皮肤科,阜阳去痘痘的医院,阜阳新皮肤白斑的治疗方法,阜阳专科痘痘,阜阳治疗斑秃医院哪家比较好

WASHINGTON, March 25 (Xinhua) -- NASA's Stardust spacecraft depleted fuel and ceased operation on Thursday after a 12-year run, the U.S. space agency said Friday."This is the end of the spacecraft's operations, but really just the beginnings of what this spacecraft's accomplishments will give to planetary science," said Lindley Johnson, Stardust-NExT and Discovery program executive at NASA headquarters in Washington."The treasure-trove of science data and engineering information collected and returned by Stardust is invaluable for planning future deep space planetary missions."Artist's concept of Stardust spacecraft nearing EarthLaunched on Feb. 7, 1999, Stardust flew past the asteroid named Annefrank and traveled halfway to Jupiter to collect the particle samples from the comet Wild 2. The spacecraft returned to Earth's vicinity to drop off a sample return capsule eagerly awaited by comet scientists.NASA re-tasked the spacecraft as Stardust-NExT to perform a bonus mission and fly past comet Tempel 1, which was struck by the Deep Impact mission in 2005. The mission collected images and other scientific data to compare with images of that comet collected by the Deep Impact.The Stardust-NExT met all mission goals, and the spacecraft was extremely successful during both missions. From launch until final rocket engine burn, it travelled approximately 3.54 billion miles.After the mileage logged in space, the Stardust team knew the end was near for the spacecraft. With its fuel tank empty and final radio transmission concluded, the most traveled comet hunter will move from NASA's active mission roster to retired."This kind of feels like the end of one of those old western movies where you watch the hero ride his horse toward the distant setting sun -- and then the credits begin to roll," said Stardust-NExT project manager Tim Larson from NASA's Jet Propulsion Laboratory in Pasadena, California. "Only there's no setting sun in space."

WASHINGTON, April 25 (Xinhua) -- Study by scientists at the Rockefeller University shows that anti-inflammatory drugs reduce the effectiveness of the most widely used class of antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs), taken for depression and obsessive-compulsive disorder and anxiety disorders.This discovery, published online Monday in the Proceedings of the National Academy of Sciences, may explain why so many depressed patients taking SSRIs do not respond to antidepressant treatment and suggests that this lack of effectiveness may be preventable.The study may be especially significant in the case of Alzheimer's disease. Such patients commonly suffer from depression and unless this can be treated successfully, the course of the illness is likely to be more severe. Depression in the elderly is also a risk factor for developing Alzheimer's Disease and researchers have suggested that treating depression in the elderly might reduce the risk of developing the disease.In the recent study, investigators treated mice with antidepressants in the presence or absence of anti-inflammatory drugs. They then examined how the mice behaved in tasks that are sensitive to antidepressant treatment. They found that the mice's behavioral responses to antidepressants were inhibited by anti- inflammatory/analgesic treatments.They then confirmed these effects in a human population. Depressed individuals who reported anti-inflammatory drug use were much less likely to have their symptoms relieved by an antidepressant than depressed patients who reported no anti- inflammatory drug use. The effect was rather dramatic since, in the absence of any anti-inflammatory or analgesic use, 54 percent of patients responded to the antidepressant, whereas success rates dropped to approximately 40 percent for those who reported using anti-inflammatory agents."Many elderly individuals suffering from depression also have arthritic or related diseases and as a consequence are taking both antidepressant and anti-inflammatory medications. Our results suggest that physicians should carefully balance the advantages and disadvantages of continuing anti-inflammatory therapy in patients being treated with antidepressant medications," leader author Paul Greengard said.

VIENNA, April 12 (Xinhua) -- A protein group has been identified as an "allergy multiplier" that causes food allergy, a symptom that could also accompany other allergies and produce serious consequences, Austrian researchers said Tuesday.The so-called non-specific lipid transfer proteins (nsLTP) are believed to be the causes of food allergy, a research team from the Medical University of Vienna said in a new report.These plant allergens are found not only in many fruits and vegetables, but also in cereals and some types of pollen. Due to their compact structures, they are not degraded in the gastrointestinal tract and can trigger immune reactions that cause severe allergic symptoms, said the report.The researchers believe that with nsLTP identified as an " allergy multiplier," diagnostic and treatment procedures could be adapted and improved.

BEIJING, May 10 (Xinhuanet) -- Professional social networking site LinkedIn is aiming for a valuation of 3.3 billion U.S. dollars for its initial public offering, media reports said Tuesday.The Mountain View, California-based company is expected to begin trading on the New York Stock Exchange within the next month and will use the symbol "LNKD."It plans to offer 7.84 million shares priced at 32 dollars to 35 dollars each, according to the filing, which it submitted to the Securities and Exchange Commission.LinkedIn, which has more than 100 million members in over 200 countries and territories, is seeking to raise as much as 274.4 million dollars from the initial public offering (IPO) with 146.6 million dollars going to the company itself.In 2010, LinkedIn made 15 million dollars in profit on 243 million dollars in revenue, according to the filing.LinkedIn's biggest shareholder is its founder and chairman, Reid Hoffman, who owns more than 21 percent of the company.

BEIJING, Jan. 29 (Xinhua) -- Chinese State Councilor Dai Bingguo and U.S. National Security Advisor Tom Donilon on Saturday both spoke highly of Chinese President Hu Jintao's state visit to the United States earlier this month.During a phone conversation, Dai and Donilon agreed that China and the United States should make joint efforts to properly implement the consensus reached by leaders on both sides and cement the achievements made during Hu's visit, which was on Jan. 18-21.They also said that the two sides should maintain the current momentum in the development of bilateral ties and devote themselves to building a cooperative partnership based on mutual respect and mutual benefit.